Thymidine kinase activity levels in serum can identify HR+?metastatic breast?cancer patients with a low risk of early progression (SWOG S0226).
Bergqvist M, Nordmark A, Williams A, Paoletti C, Barlow W, Cobain EF, Mehta RS, Gralow JR, Hortobagyi GN, Albain KS, Pusztai L, Sharma P, Godwin AK, Thompson AM, Hayes DF, Rae JM. Thymidine kinase activity levels in serum can identify HR+?metastatic breast?cancer patients with a low risk of early progression (SWOG S0226). Biomarkers. 2023 Jan 29; 1-10.